Malaria Clinical Trial
Official title:
A Study of the Impact of Insecticide-treated Curtains on the Prevalence of Antimalarial Drug Resistance in Children With Uncomplicated Malaria in Burkina Faso
Attempts to understand the relationship malaria transmission intensity and antimalarial drug resistance had rested mainly on mathematical models. To date, except for two studies which reported reductions in the prevalence of drug resistance in Tanzania and Zimbabwe, no other field data addressed the impact of reducing malaria transmission by the use of vector control measures on antimalarial drug resistance. Thus whether vector control decrease or increase drug resistance remains a contentious issue. The aim of this study was to investigate the impact of insecticide-treated curtains (ITCs) on clinical and parasitological outcomes in children with uncomplicated malaria treated with chloroquine (CQ), on the prevalence of genetic markers of resistance to CQ and sulphadoxine-pyrimethamine (SP) and on the ability of children to clear drug resistant parasites. The therapeutic efficacy of CQ was studied in 9 villages which used ITCs for 6-8 years and 9 villages with no history of ITC use. A cross-sectional survey was also conducted to estimate the prevalence of genetic markers of resistance to CQ and SP in asymptomatic children.
1. Background
Drug resistance has been associated with increased numbers of hospital admissions,
increased cases of clinical malaria and malaria-specific mortality . Several strategies
have been proposed as means by which the spread of antimalarial drugs resistance could
be delayed. These strategies include reducing drug pressure, improving the quality of
drug use, using combinations of antimalarial drugs and use of vector control measures.
Restricting the use of drugs to reduce drug pressure is presently unrealistic due to
poor access to health facilities and a lack of equipment. Improving the quality of use
of antimalarials through the use of pre-packaged doses, education and training is a
sound control strategy. However, the impact of this strategy on drug resistance has not
yet been evaluated. Another promising approach to contain drug resistance is the use of
combination therapies. The most successful combinations so far are those using
artemisinin and its derivatives. It is likely that implementing combination therapy in
resource limited countries will be hampered by its high cost. Given their impact in
reducing malaria transmission, cases of clinical malaria and all-cause malaria
mortality, insecticide-treated materials (ITMs) have recently been proposed as a
potential tool for delaying the development and spread of drug resistance. So far, the
debate on the interaction between malaria transmission intensity and drug resistance
has been driven by analytical models and, to our knowledge, only 2 field studies have
yet addressed the impact of ITMs on antimalarial drug resistance. If ITMs reduced the
development and spread of antimalarial drug resistance, this would enhance their
usefulness as a malaria control tool. This study examines the impact of
insecticide-treated curtains (ITC)used over 6-8 years on the prevalence of antimalarial
drug resistance in Burkina Faso.
2. Objectives
2.1 Primary objectives
- To determine the frequency of in vivo clinical and parasitological failures
following treatment of uncomplicated malaria with CQ in children living in
villages protected and not protected by insecticide treated curtains (ITC).
- To determine if children in ITC and non-ITC villages with clinical malaria differ
in their ability to clear genetically resistant parasites after treatment with CQ.
2.2 Secondary objectives
- To determine the proportions of children infected with parasites carrying the
pfcrt-76T and pfmdr1-86Y alleles associated with resistance to CQ in villages
protected and not protected by ITC.
- To determine the proportions of children infected with parasites carrying
parasites with the dihydrofolate reductase (dhfr) and dihydropteroate synthetase
(dhps) alleles associated with resistant to SP in ITC and non- ITC protected
villages.
- To relate in vivo clinical and parasitological failure rates to the presence of
genotypic markers of resistance to CQ by estimating genotype-failure indices
(GFIs) and genotype-resistance indices (GRIs).
3. Methods
3.1 Field work
Passive case detection was used to recruit children aged 6-59 months with uncomplicated
malaria using a slightly modified version of the standard WHO in vivo method for assessing
therapeutic efficacy of anti-malarial drugs .Children seeking care at the selected health
centres were screened for eligibility to join the study, enrolled and followed up for 14
days. If a child's axillary temperature was >=37.5 ºC and no obvious cause of fever other
than malaria was found on clinical examination, about 500 ml of blood was drawn into a
micro-container containing EDTA. Microscopic diagnosis of malaria and measurement of
packed-cell volume (PCV) were performed immediately after samples were received in the
laboratory. After enrolment, further clinical examinations were performed on days 1, 2, 3,
7, and 14. In addition, the caretakers were advised to bring children back to the health
centre at any time between day 1 and day 14 if the child's condition did not improve. Thick
and thin blood films and filter paper blood spots were prepared on days 0, 3, 7, 14 and at
unscheduled visits.
Treatment of children and treatment outcome
A standard treatment with CQ was administered to children with uncomplicated malaria. The
treatment dosing was 25 mg/kg body weight of CQ over 3 days; 10 mg/kg on days 0, 1 and 5
mg/kg on day 2. Treatment was administered at the clinic under the supervision of a nurse.
Outcomes for the in vivo trial were classified according to the WHO clinical and
parasitological assessment system
Prevalence of pfcrt-76 and pfmdr1-86 mutations in the community
A cross-sectional survey was conducted to estimate the prevalence of pfcrt-76 and pfmdr1-86
mutations in asymptomatic children. Random samples of children aged 6 to 59 months and
children aged 5 years to 14 years were selected per village. Thick and thin blood films and
filter paper blood spots were prepared from a finger-prick.
Estimation of the entomological inoculation rate
A cross-sectional survey was conducted at the peak period of malaria transmission (September
2002) for the estimation of the EIR. Catches were performed using CDC light traps. An ELISA
test was used to detect the presence of P. falciparum circumsporozoite protein (CSP).
Socio-economic and health seeking behaviour survey
In 2003, a survey was performed in a random sample of 20 compounds in each village to
collect data on health seeking behaviour, socio-economic and demographic features of the
study population including the frequencies of population movements between villages.
3.2 Laboratory methods
Thick and thin blood films were stained with Giemsa stain (3%) for 45 minutes. Asexual
parasites and gametocytes of P. falciparum were counted against 400 white blood cells. For
molecular biology analyses, DNA was extracted from pre, post-treatment and cross-sectional
survey filter paper blood spots using chelex. DNA was amplified by nested PCR to detect
mutations at pfcrt-76. Nest 2 PCR products were digested by Apo I endonuclease restriction
enzyme and electrophoresed onto a 3% agarose. Sequence-specific oligonucleotide probing
(SSOP) was performed to detect the presence of pfmdr1-86 mutation. Mutations at dhfr (51, 59
and 108) and at dhps ( 437 and 540) were also detected by SSOP. MSP2 gene polymorphisms were
studied by PCR to differentiate recrudescence from new infections.
3.3 Sample size and power
With 18 communities (9 per group), the study would have 80% power to detect, at the 5%
significance level, a 50% decrease in clinical failure rate in eligible children. This
number of communities would also permit the detection of a 40% decrease in parasitological
failure rate in eligible children with the same power, and at least 60% and 40% increases in
clinical and parasitological failure rates, at 5% significance level, in children carrying
parasites with CQ resistant genotypes before CQ treatment was started.
3.4 Data processing and analyses
Two data clerks independently entered data onto computers using EPIINFO version 6.0.
Analyses were performed using STATA (Release 8.2, www.stata.com). The study main endpoints
were examined using Generalized Estimating Equations regression model
3.5 Community approval
This was obtained after meetings with community leaders to explain the objectives of the
study and what it involved. In addition to community consent, individual signed informed
consent was obtained from caretakers of children before enrolment.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Completed |
NCT02315690 -
Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland
|
Phase 3 |